Relationship between thyroid function abnormality and sindilizumab treatment effic-acy in patients with advanced gastric cancer
10.12354/j.issn.1000-8179.2025.20250862
- VernacularTitle:胃癌晚期患者信迪利单抗治疗后甲状腺功能异常与疗效之间的关系
- Author:
Gao WENHUA
1
;
Mou KUN
1
;
Fu YUAN
1
;
Dai HUAN
1
Author Information
1. 济南市人民医院肿瘤科(济南市 271100)
- Publication Type:Journal Article
- Keywords:
advanced gastric cancer;
sindilizumab;
thyroid function abnormality;
efficacy
- From:
Chinese Journal of Clinical Oncology
2025;52(17):877-883
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the factors in fluencing thyroid function abnormality(TFA)and its relationship with the clinical efficacy of sindilizumab treatment in patients with advanced gastric cancer.Methods:The clinical data of 180 patients with advanced gastric cancer treated with sintilimab at Jinan People's Hospital from January 2021 to June 2024 were retrospectively reviewed.Patients were assigned in-to the TFA group and the normal control group according to thyroid function.Factors influencing the occurrence of TFA were investigated using the χ2 test and multifactorial Logistic regression.Kaplan-Meier analysis and the Log-rank test were used for comparison between groups.Univariate and multivariate Cox regression were used to assess the correlation between TFA and therapeutic efficacy.Results:A total of 52 patients developed TFA.Univariate analysis showed that history of thyroid nodule,treatment regimen,liver metastasis,and car-cinoembryonic antigen(CEA)were associated with the development of TFA.Multifactorial Logistic regression analysis showed that history of thyroid nodule,treatment regimen,and CEA were independent risk factors for the development of TFA(P<0.05).The objective response rate(ORR;34.6%vs.14.1%,P=0.002),disease control rate(DCR;69.2%vs.59.8%,P=0.024),and 1-year survival rate(59.6%vs.28.9%,P=0.012)were all better in the normal control group than those in the TFA group.Cox regression analysis showed that occurrence of TFA,liver meta-stasis,and≥6 treatment cycles were all independently associated with progression-free survival and overall survival in patients with ad-vanced gastric cancer(P<0.05).Conclusions:History of thyroid nodule,treatment regimen,and CEA may influence the occurrence of TFA.TFA may be a potential predictor of the efficacy of sindilizumab therapy for advanced gastric cancer,with patients who develop TFA poten-tially having better treatment outcomes.
